Literature DB >> 27344650

Swallow Prognosis and Follow-Up Protocol in Infantile Onset Pompe Disease.

Gyani Swift1, Maureen Cleary2, Stephanie Grunewald2, Sonia Lozano3, Martina Ryan3, James Davison2.   

Abstract

Oro-pharyngeal dysphagia commonly occurs in patients with infantile onset Pompe disease (IOPD), which is a rare recessive neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase. Without treatment, death occurs by 1 year of age from cardiorespiratory failure. Enzyme replacement therapy (ERT) has been used to increase life expectancy, however emerging developmental and medical morbidities have become apparent. A case file review of the feeding outcomes of 12 patients with IOPD, managed at a single tertiary centre, was undertaken. Two types of assessment had been completed: clinical feeding assessment (CFA) and instrumental videofluoroscopy swallow study (VFSS). A rating of functional oral intake at every Speech and Language Therapy feeding assessment from initial diagnosis to the most recent assessment was applied using the functional oral intake scale (FOIS).Results indicate, initial diagnosis VFSS predicts long-term feeding outcomes. Even if a patient had an improvement in oral feeding after diagnosis, over a period of time their oral intake returned to the initial diagnosis VFSS level or below. All patients (8/8) who required non-oral feeding support under 6 months of age went on to require non-oral feeding support, even if they had periods of full oral feeding. CRIM negative status predicted significant oral feeding difficulties. An evidence-based follow-up protocol was developed. The information is used at diagnosis to counsel families regarding feeding prognosis and consideration of early gastrostomy when cardiac status allows safe anaesthesia. The results reinforce that feeding changes over time and patients require on-going dysphagia monitoring.

Entities:  

Keywords:  Enzyme replacement therapy; Feeding; Functional oral intake scale; Infantile onset Pompe disease; Oro-pharyngeal dysphagia

Year:  2016        PMID: 27344650      PMCID: PMC5413449          DOI: 10.1007/8904_2016_576

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  9 in total

1.  Reliability and validity of cervical auscultation: a controlled comparison using videofluoroscopy.

Authors:  Paula Leslie; Michael J Drinnan; Paul Finn; Gary A Ford; Janet A Wilson
Journal:  Dysphagia       Date:  2004       Impact factor: 3.438

2.  Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients.

Authors:  Michael A Crary; Giselle D Carnaby Mann; Michael E Groher
Journal:  Arch Phys Med Rehabil       Date:  2005-08       Impact factor: 3.966

3.  Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience.

Authors:  Anupam Chakrapani; Ashok Vellodi; Peter Robinson; Simon Jones; J E Wraith
Journal:  J Inherit Metab Dis       Date:  2010-09-24       Impact factor: 4.982

4.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

5.  Oropharyngeal dysphagia in infants and children with infantile Pompe disease.

Authors:  Harrison N Jones; Carolyn W Muller; Min Lin; Suhrad G Banugaria; Laura E Case; Jennifer S Li; Gwendolyn O'Grady; James H Heller; Priya S Kishnani
Journal:  Dysphagia       Date:  2009-09-10       Impact factor: 3.438

6.  Age-specific reference intervals for indexed left ventricular mass in children.

Authors:  Philip R Khoury; Mark Mitsnefes; Stephen R Daniels; Thomas R Kimball
Journal:  J Am Soc Echocardiogr       Date:  2009-05-07       Impact factor: 5.251

7.  The emerging phenotype of long-term survivors with infantile Pompe disease.

Authors:  Sean N Prater; Suhrad G Banugaria; Stephanie M DeArmey; Eleanor G Botha; Erin M Stege; Laura E Case; Harrison N Jones; Chanika Phornphutkul; Raymond Y Wang; Sarah P Young; Priya S Kishnani
Journal:  Genet Med       Date:  2012-04-26       Impact factor: 8.822

8.  Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy.

Authors:  C M van Gelder; C I van Capelle; B J Ebbink; I Moor-van Nugteren; J M P van den Hout; M M Hakkesteegt; P A van Doorn; I F M de Coo; A J J Reuser; H H W de Gier; A T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2011-10-19       Impact factor: 4.982

9.  Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy.

Authors:  Simona Fecarotta; Serena Ascione; Giuseppe Montefusco; Roberto Della Casa; Paola Villari; Alfonso Romano; Ennio Del Giudice; Generoso Andria; Giancarlo Parenti
Journal:  Ital J Pediatr       Date:  2013-05-13       Impact factor: 2.638

  9 in total
  3 in total

Review 1.  Long-term outcome and unmet needs in infantile-onset Pompe disease.

Authors:  Andreas Hahn; Anne Schänzer
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Congenital or Early Developing Neuromuscular Diseases Affecting Feeding, Swallowing and Speech - A Review of the Literature from January 1998 to August 2021.

Authors:  Lotta Sjögreen; Lisa Bengtsson
Journal:  J Neuromuscul Dis       Date:  2022

3.  Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction.

Authors:  Cindy Li; Ankit K Desai; Punita Gupta; Katherine Dempsey; Vikas Bhambhani; Robert J Hopkin; Can Ficicioglu; Pranoot Tanpaiboon; William J Craigen; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2021-01-25       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.